Eli Lilly and Company has officially broken ground on a massive $6.5 billion active pharmaceutical ingredient (API) manufacturing campus in Houston, Texas. The facility marks the pharmaceutical giant’s tenth U.S. manufacturing expansion announced since 2020 and its fifth dedicated domestic API production hub, forming a cornerstone of the company’s broader $50 billion reshoring initiative.

“Texas is the global hub for life sciences,” says Texas Governor Greg Abbott. “This $6.5 billion Lilly investment in Houston is the largest active pharmaceutical ingredient project in Texas history.”

Spanning a critical role in Lilly’s commercial pipeline, the new Houston plant will primarily focus on manufacturing active ingredients for its portfolio of small-molecule therapies, spearheaded by Foundayo (orforglipron). As an oral GLP-1 receptor agonist designed for chronic weight management and obesity-related co-morbidities, Foundayo represents a distinct technological shift from peptide-based injectables. Because small molecules rely on more established chemical synthesis frameworks, the Houston site is engineered to scale production rapidly to meet soaring global demand ahead of a projected 2027 commercial rollout.

Beyond oral metabolic treatments, the facility will also accommodate production lines for advanced therapeutics, including oligonucleotides designed to target diseases at the genetic level by intercepting aberrant protein expression.

To staff the facility, Lilly has committed $12.5 million toward establishing specialized workforce training pathways in partnership with San Jacinto College, alongside a $2.5 million contribution to the college’s foundation for student scholarships. The collaboration aims to prepare regional talent for high-wage technical roles—such as chemical operators, automation engineers, and lab technicians—without requiring prior industry background. When fully operational, the campus is projected to create more than 600 permanent high-wage positions, building on an estimated 4,000 construction jobs required during the build-out phase.

Reflecting the industry’s digital transformation, the Houston facility will embed advanced automation technologies, including machine learning algorithms, artificial intelligence, and real-time data analytics, to optimize yields, ensure rigorous quality control, and fortify the domestic pharmaceutical supply chain.

For more information, visit www.lilly.com.